Skip to main content
OpenTrials
Completed

NCT Number: NCT05050669

Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency

The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes) of each disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Sainte-Justine, Montreal, Quebec, Canada

Loading trial locations.

About this study

Study INZ701-003 is a multicenter, prospective, longitudinal, observational study to evaluate disease presentation, progression, and burden of illness in pediatric subjects aged 2 to <18 years with ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency. Subjects will receive care available at the clinical site along with additional assessments administered by the study team.

To participate in this study, subjects will give informed assent and parents/guardians will provide informed consent.

Subject participation will consist of a Screening Period and an Observation Period.

Assessments will be performed at each visit as indicated in the Schedule of Events.

During the Screening Period, assessments will be performed to determine eligibility.

Screening and Baseline assessments may be conducted on the same day if the Investigator determines that the patient can successfully complete all study procedures in one day due to their age. If not, sites may schedule additional visits, as needed. A subject will be enrolled into the study if they meet all eligibility criteria.

During the Observation Period, subjects will be assessed for changes in their disease in the following areas: measurements of physiological function (including laboratory testing and anatomical and radiographical assessment of calcification and bone mineralization); performance outcomes; patient, caregiver, and physician reported outcomes; and healthcare utilization.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Individuals eligible to participate must meet all of the following inclusion criteria:

  • Must provide written consent of the legally authorized representative/caregiver and assent for subjects after the nature of the study has been explained and prior to any research-related procedures, following the policies of the clinical site
  • Genetic confirmation of ENPP1 Deficiency or ABCC6 Deficiency
  • Male or female, aged 2 to <18 years
  • In the opinion of the Investigator, must be willing and able to complete all aspects of the study
  • Agree to provide access to relevant medical records

Exclusion criteria

Individuals who meet the following exclusion criterion will not be eligible to participate:

  • In the opinion of the Investigator and/or Sponsor, presence of any clinically significant disease (outside of those considered associated with the diagnosis of ENPP1 Deficiency or the early-onset form of ABCC6 Deficiency) that precludes study participation or may confound interpretation of study results, such as an unrelated bone, mineral, or muscle disease or genetic connective tissue disease

Treatment and study plan

No Intervention for this observational study

Other

No Intervention for this observational study

Primary outcomes

  1. Measurement of Plasma Inorganic Pyrophosphate (PPi) in Plasma

    Time frame: Up to 12 months

    For each subject, blood plasma will be assayed for Plasma Inorganic Pyrophosphate (PPi), comparing the subjects baseline value over time

  2. Determination of Arterial Calcification

    Time frame: Up to 12 months

    For each subject, occurrence of arterial calcification will be examined

  3. Determination of Organ Calcification

    Time frame: Up to 12 months

    For each subject, occurrence of organ calcification will be examined

  4. Determination of skeletal radiographs

    Time frame: Up to 12 months

    For each subject, skeletal radiographs will be obtained to determine skeletal abnormalities and will be compared to baseline

  5. Determination of range of motion

    Time frame: Up to 12 months

    For each subject, aged 4 to <18 years, range of motion will be assessed comparing to subjects baseline over time

Sponsors and collaborators

Lead sponsor

Inozyme Pharma

Industry

Registry information

Official study title

A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Sep 20, 2021
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.